Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Multiple adjusted analysis of ASAS40 response in different BMI categories at 1 year of treatment with a first TNF inhibitor

From: Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis

  Model 1 Model 2
Variable OR 95% CI p OR 95% CI p
Obese (ref: normal BMI) 0.27 0.09–0.70 0.01 0.18 0.05–0.59 0.008
Overweight (ref: normal BMI) 0.62 0.24–1.14 0.13 0.66 0.34–1.30 0.23
Age 1.01 0.99–1.04 0.32 1.01 0.98–1.04 0.36
HLA-B27 1.31 0.65–2.68 0.46 1.35 0.67–2.79 0.41
Male sex 2.41 1.28–4.66 0.007 2.57 1.35–5.01 0.005
nr-axSpA (ref: AS) 0.38 0.18–0.78 0.009 0.38 0.18–0.78 0.01
Current smoking yes vs. no 0.65 0.36–1.18 0.16 0.64 0.35–1.16 0.15
Exercise (ref: no exercise) 0.89 0.50–1.58 0.69 0.83 0.46–1.50 0.54
BASDAI 1.10 0.95–1.27 0.19 1.10 0.95–1.27 0.20
BASMI 0.76 0.63–0.90 0.002 0.75 0.63–0.89 0.002
Elevated CRP 1.69 0.94–3.08 0.08 1.65 0.91–3.03 0.10
Enthesitis 1.34 0.72; 2.52 0.36 1.29 0.69; 2.43 0.43
DMARDs 1.17 0.51; 2.71 0.71 1.14 0.48; 2.67 0.76
NSAIDs 1.21 0.39; 4.24 0.75 1.13 0.35; 4.07 0.84
Infliximab (ref: other TNFi)     0.66 0.26–1.65 0.37
Obese with infliximab (ref: other TNFi)     3.55 0.41–30.1 0.24
Overweight with infliximab (ref: other TNFi)     0.73 0.15–3.26 0.68
  1. Analysis performed in 259 patients
  2. AS Ankylosing Spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASMI Bath Ankylosing Spondylitis Mobility Index, BMI body mass index, CI confidence interval, CRP C-reactive peptide, DMARDs disease-modifying antirheumatic drugs, HLA-B27 human leucocyte antigen-B27, nr-axSpA nonradiographic axial spondyloarthritis. NSAIDs nonsteroidal anti-inflammatory drugs, OR odds ratio, ref reference, TNFi tumor necrosis factor inhibitor